Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent KV7 Potassium Channel Opener, in Adults With Focal Epilepsy: ≥48-Month Interim Analysis of the Ongoing 7-Year X-TOLE Open-Label Extension | Xenon Pharmaceuticals Inc.

Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent KV7 Potassium Channel Opener, in Adults With Focal Epilepsy: ≥48-Month Interim Analysis of the Ongoing 7-Year X-TOLE Open-Label Extension

September 7, 2026

Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent KV7 Potassium Channel Opener, in Adults With Focal Epilepsy: ≥48-Month Interim Analysis of the Ongoing 7-Year X-TOLE Open-Label Extension 426.8 KB

Tags

Azetukalner in Epilepsy

Congress: European Epilepsy Congress (September 6, 2026)
Authors: French JA, et al.
Encore of AES 2025

Investor inquiries

Tucker Kelly
Chief Financial Officer
investors@xenon-pharma.com

Request Information

Email alerts

Sign up here to receive email alerts from Xenon Pharmaceuticals